FOLD
MaterialsAmicus Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving FOLD Today?
No stock-specific AI insight has been generated for FOLD yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
FOLD News
20 articles- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley SaysYahoo Finance·May 5, 2026
- BioMarin acquires Amicus Therapeutics for $4.8bnPharmaceutical-technology·Apr 28, 2026
- CIBRA Capital Buys Stake in Allied Gold StockMotley Fool·Apr 27, 2026
- BioMarin Completes Acquisition of Amicus TherapeuticsYahoo Finance·Apr 27, 2026
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)The Motley Fool·Apr 25, 2026
- Here is Why BioMarin (BMRN) is Projected to RallyYahoo Finance·Mar 31, 2026
- Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total ReturnYahoo Finance·Mar 29, 2026
- Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?Yahoo Finance·Mar 27, 2026
- Tarsus Pharmaceuticals Stock Earns Upgrade To RS RatingYahoo Finance·Mar 26, 2026
- Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Mar 26, 2026
- BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Mar 25, 2026
- Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF UpsideYahoo Finance·Mar 15, 2026
- Viking Therapeutics Stock Gets RS Rating UpgradeYahoo Finance·Mar 10, 2026
- Rice Hall James Loads Up on BIRK With 466,000 Shares BoughtMotley Fool·Mar 9, 2026
- Rice Hall James Buys QuidelOrtho StockMotley Fool·Mar 9, 2026
- Rice Hall James Buys Stride StockMotley Fool·Mar 9, 2026
- How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease PortfolioYahoo Finance·Mar 6, 2026
- Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor FocusYahoo Finance·Mar 5, 2026
- Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC FilingMotley Fool·Mar 3, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Amicus Therapeutics Inc
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.